Plug-and-Play Vaccines?

The SARS scare proves a boon to a small and nimble outfit with some timely expertise in gene therapies

Ten years ago, Genvec was founded to cure disease by delivering new genes to people with illnesses such as cystic fibrosis. So far, such gene therapy hasn't led to products. But the Gaithersburg (Md.) company believes its technology will pay off -- in vaccines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.